Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study

Sequential HER2-targeted therapy as the first post-T-DXd treatment in HER2-positive mBC was feasible and demonstrated clinical benefit, particularly in patients who discontinued T-DXd treatment due to AEs and those who achieved a response to T-DXd. Patients who developed ILD during T-DXd treatment had a low risk of recurrence/exacerbation in subsequent therapy.